literature

HBV mutation literature information.

Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.

PMID: 26825915 2016 Medicine

Result: In the PVR group, all treatment-naive patients harbored rtA181 V/T substitutions (ranging from 1.1% to 3.8%) and rtN236T substitutions (ranging from 1.5% to 6.1%).

Discussion: One study reported that the most commonly detected mutations were M204 V/I, M250 V/I, A181T/V, and N236T.

Discussion: UDPS indicated that NAr mutations were pre-existent at low percentages (ranging from 0.1% to 6.7%) at baseline, including rtV173A/M, rtL180 M, rtA181 V/T,

Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.

PMID: 26831605 2016 Saudi journal of gastroenterology

Introduction: In general, the majority of HBV rtA181V/T mutants are known to be induced after ADV therapy, along with the rtN236T mutant.

Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.

PMID: 26876337 2016 The Brazilian journal of infectious diseases

Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &

HBV/4DR 9G test and its comparison with INNO-LiPA HBV multi-DR test for the detection of drug-resistant Hepatitis B virus.

PMID: 27581951 2016 Journal of virological methods

Abstract: The rtA181V, rtM204V/I, rtN236T and, rtM250V are high prevalent mutations found in the drug-resistant HBV strains.

Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.

PMID: 27602500 2016 Oncotarget

Abstract: RESULTS: At baseline, all 46 treatment-naive patients harbored rtA181V/T substitutions (1.2%-4.6%) and rtN236T substitutions (1.6%-6.1%).

Abstract: and two patients (NOs.4 and 8) carrying the rtA181T resistance mutations increasingly showed high levels of rtN236T.

Introduction: HBV mutants resistant to adefovir (ADV) monotherapy are complex and diverse, including rtA181T, rtV214A, and rtN236T.

Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.

PMID: 28139541 2016 The Indian journal of medical research

Abstract: Mutations: rtM204V (39.3%), M204V+L180M (10.7%) while rtA181V (8.1%) and rtN236T (8.3%) were observed with LAM and ADV regimen, respectively.

Result: VBT on ADV monotherapy was noted in eight patients (33.3%), rtA181T and rtN236T mutants were detected alone in 8.1 and 8.3 per cent in the conserved regions B and D of rt region of HBV polymerase gene, respectively.

Discussion: Of the total 16.4 per cent with ADV mutation, sites detected were adenine substitution to threonine i.e.,

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.

PMID: 26889227 2016 Experimental and therapeutic medicine

Result: 2A is summarized as follows: i) No substitution was detected in the baseline sample; ii) the rtN236T substitution was present in ~10% of the viral population, whereas the wild-type virus was predominantly repressed at month 12.

Result: The rtN236T reappeared at month 24 with the viral load fluctuation and was undetectable when outgrowth of the ETV-resistant variants was observed; iii) among the LAM-resistant variants, the rtM204I

Discussion: Furthermore, with prolonged treatment, whether the ADV-resistant variant (rtA181V/T or rtN236T) will be selected and linked with the ETV-resistant strain warrants additional investigation.

Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.

PMID: 27313669 2016 Experimental and therapeutic medicine

Result: ADV-resistant variant rtN236T decreased and became undetected following 2 years of combination therapy.

Result: ADV-resistant variants rtA181 V/T and rtN236T went from being dominant at initiation of ADV-ETV combination to undetectable, during an average duration of combination therapy of 19.33 months (range, 11-24 months).

Result: During sequential monotherapy, the levels of LAM-resistant variants (rtM204I/V with or without rtL180 M) gradually decreased as treatment progressed, whereas ADV-resistant rtA181 V/T and

PMID: 27079793 2016 Annals of clinical microbiology and antimicrobials

Result: The rtN236 T mutation was not found by direct sequencing of PCR products, and no ETV-resistance mutations were detected in this patient.

Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.

PMID: 27504160 2016 Electronic physician

Result: N236T and compensatory mutation (A181T/P) were found to be between 3.2 and 6.4%, respectively (Table 2).

Result: Again, N236T, which is related to ADV therapy, was absent in this group (Table 2).

Result: No ADV-related variant N236T was found in this group.

Browser Board

Co-occurred Entities

Filtrator